-

12:42:49 PM

EW Stock News

EW - Edwards Lifesciences Corp

01/19/22 7:05 AM

NYSE : EW

conferencesearnings

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JANUARY 26, 2022

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2021 after the market closes on Wednesday, January 26, 2022, and will host a conference call at 5:00 p.m. ET that day to discuss those

RHEA-AI

neutral

01/05/22 8:10 AM

NYSE : EW

conferences

EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate at the J.P. Morgan Healthcare Conference on Monday, January 10, 2022.Michael A. Mussallem, chairman and chief executive officer, is scheduled to present virtually at 11:15

RHEA-AI

neutral

12/20/21 9:05 AM

NYSE : EW

fda approval

EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT

Edwards Lifesciences (NYSE: EW) today announced it received approval from the U.S. Food and Drug Administration (FDA) for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (SAPIEN 3 with Alterra) for patients with

RHEA-AI

positive

12/08/21 9:05 AM

NYSE : EW

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance 1 today during its annual investor conference.Highlights of today's

RHEA-AI

neutral

11/06/21 1:47 PM

NYSE : EW

Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program

Edwards Lifesciences Corporation (NYSE: EW) announced that results from a clinical trial of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months. Results from the

RHEA-AI

neutral

11/05/21 11:20 AM

NYSE : EW

partnership

TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis

Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved

RHEA-AI

very positive

10/27/21 4:15 PM

NYSE : EW

Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2021.Third Quarter Highlights and 2021 OutlookSales grew 15 percent to $1.3 billion; underlying 1 sales grew 14 percent TAVR sales grew 15 percent;

RHEA-AI

positive

10/20/21 7:05 AM

NYSE : EW

conferencesearnings

Edwards Lifesciences To Host Earnings Conference Call On October 27, 2021

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2021 after the market closes on Wednesday, October 27, 2021, and will host a conference call at 5:00 p.m. ET that day to discuss those

RHEA-AI

neutral

07/29/21 4:15 PM

NYSE : EW

Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021.Second Quarter Highlights and 2021 OutlookSales rebounded and grew 49 percent to $1.4 billion; underlying 1 sales grew 44 percent TAVR sales exceeded

RHEA-AI

positive

07/22/21 3:15 PM

NYSE : EW

Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR

Edwards Lifesciences (NYSE: EW) today announced that clinical and economic results from the 3M (multidisciplinary, multimodality, but minimalist) Transcatheter Aortic Valve Replacement (TAVR) Economic Study and the PARTNER 3 Bicuspid Registry for SAPIEN

RHEA-AI

positive